Pan-cancer multi-omics analysis and orthogonal experimental assessment of epigenetic driver genes

Genome Res. 2020 Oct;30(10):1517-1532. doi: 10.1101/gr.268292.120. Epub 2020 Sep 22.

Abstract

The recent identification of recurrently mutated epigenetic regulator genes (ERGs) supports their critical role in tumorigenesis. We conducted a pan-cancer analysis integrating (epi)genome, transcriptome, and DNA methylome alterations in a curated list of 426 ERGs across 33 cancer types, comprising 10,845 tumor and 730 normal tissues. We found that, in addition to mutations, copy number alterations in ERGs were more frequent than previously anticipated and tightly linked to expression aberrations. Novel bioinformatics approaches, integrating the strengths of various driver prediction and multi-omics algorithms, and an orthogonal in vitro screen (CRISPR-Cas9) targeting all ERGs revealed genes with driver roles within and across malignancies and shared driver mechanisms operating across multiple cancer types and hallmarks. This is the largest and most comprehensive analysis thus far; it is also the first experimental effort to specifically identify ERG drivers (epidrivers) and characterize their deregulation and functional impact in oncogenic processes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CRISPR-Cas Systems
  • Cell Proliferation / genetics
  • Computer Simulation
  • DNA Methylation
  • Epigenesis, Genetic*
  • Epigenomics
  • Epithelial-Mesenchymal Transition / genetics
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic*
  • Genes, Neoplasm*
  • Humans
  • Neoplasms / genetics*
  • Neoplasms / pathology
  • RNA, Neoplasm / metabolism

Substances

  • RNA, Neoplasm